

**PATIENT INFORMATION**

Patient Name: \_\_\_\_\_ DOB: \_\_\_\_\_ Phone: \_\_\_\_\_ Sex: M F Ht: \_\_\_\_\_ Wt: \_\_\_\_\_ lbs kg

Primary Language: \_\_\_\_\_ Allergies: \_\_\_\_\_

**Patient Preferred Location:** \_\_\_\_\_**<ICD 10 CODE REQUIRED> DIAGNOSIS & CLINICAL INFORMATION****ICD 10 Code**

J45.51 Severe Persistent Asthma, w/Acute Exacerbation

J45.50 Severe Persistent Asthma, Uncomplicated

Other: \_\_\_\_\_

**REQUIRED:** Demographics & Most Recent: H&P, clinical notes, & medication list. Supporting clinical notes to include any past tried and/or failed therapies, intolerance, outcomes, or contraindications to conventional therapy.  
**LAB RESULTS:** Blood eosinophil level OR CBC with differential AND pulmonary function test prior to initiating therapy.

**PRESCRIPTION****FASENRA (benralizumab)****Loading Dose****SubQ:** Inject 30 mg every 4 weeks for the first 3 doses**Maintenance Dose****SubQ:** Inject 30 mg every 8 weeks for one year**Post Treatment Observations:** The patient is observed for 30 minutes following the first administration.**Adverse Events:** In the event of an adverse reaction occurring at a Medix Infusion suite, utilize the Medix Infusion adverse reactions protocol.**Comments:**\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_**PRESCRIBER INFORMATION**

Prescriber Name: \_\_\_\_\_ Signature: \_\_\_\_\_

Date: \_\_\_\_\_ NPI #: \_\_\_\_\_ Specialty: \_\_\_\_\_

Supervising Physician: \_\_\_\_\_ (If Applicable)

Address: \_\_\_\_\_ City: \_\_\_\_\_ State: \_\_\_\_\_ Zip: \_\_\_\_\_

Contact Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Email: \_\_\_\_\_